Please assess the completion status of the following clinical trial:

Trial Title: Cheno Effect on Transit in Health and IBS-C

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Healthy volunteers:~* Age (yr) 18-65~* Gender (F:M)3.5 :1~* Bowel Disease Questionnaire (BDQ) - IBS symptoms negative by Rome III criteria~* Hospital Anxiety/Depression score \<8~IBS patients:~* Age (yr) 18-65~* Gender (F:M) 5 :1~* BDQ - IBS symptoms: positive by Rome III criteria~* Hospital Anxiety/Depression score: No restrictions~Exclusion Criteria:~* Abdominal surgery (except appendectomy or cholecystectomy)~* GI medications during the 48h prior to transit measurement~* Aspartate/Alanine transaminases \>2 X Upper Limit of Normal (ULN)~* Other Medications except stable doses of estrogen, thyroid, low dose antidepressants of the dopaminergic or serotonergic class

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- NaCDC 500 mg (Type: EXPERIMENTAL): Participants randomized to this arm received 500 mg NaCDC per day for 4 days.
- NaCDC 1000 mg (Type: EXPERIMENTAL): Participants randomized to this arm received 1000 mg NaCDC per day for 4 days.
- Placebo (Type: PLACEBO_COMPARATOR): Participants randomized to this arm received a placebo capsule each day for 4 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).